Imetelstat for Rare Blood Cell Disorders
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a drug called imetelstat in patients with rare blood disorders (CMML and MDS/MPN). The drug may help by stopping abnormal blood cells from growing and reduce symptoms like tiredness and enlarged spleen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with CMML or MDS/MPN (rare blood cancers) and meet specific criteria—for example, your disease didn't respond to previous treatments or you couldn't tolerate them
- Your liver and kidney function are adequate (specific blood test levels required)
- You are able to care for yourself with minimal help (ECOG score of 2 or better)
- If you can have children, you agree to use reliable birth control during and for 30 days after the study
- You have not received imetelstat before and are not currently in another drug study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Hear when a new Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.